SCHEMBL5145444

SCHEMBL5145444

O=C1C(=O)c2cc3cc4ccccc4cc3cc2-c2ccccc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 8/20 0.59
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
S100A4 P26447 4/20 0.59
NPC1 O15118 4/20 0.59
RAB9A P51151 4/20 0.59
APAF1 O14727 3/20 0.59
LMNA P02545 3/20 0.59
HTT P42858 3/20 0.59
GALK1 P51570 3/20 0.59
BLM P54132 3/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
NPSR1 Q6W5P4 3/20 0.59
MAPK1 P28482 3/20 0.59
TDP2 O95551 2/20 0.59
PLA2G1B P04054 2/20 0.59
POLB P06746 2/20 0.59
PLCG1 P19174 2/20 0.59
PPARG P37231 2/20 0.59
ATG4B Q9Y4P1 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2198881 0.95 PTPRC (0.65) PTPRCMEN1KMT2AS100A4NPC1
SCHEMBL652915 0.91 MEN1 (0.60) PTPRCMEN1KMT2AS100A4NPC1
SCHEMBL29634247 0.91 MEN1 (0.60) PTPRCMEN1KMT2AS100A4NPC1
SCHEMBL347152 0.91 MEN1 (0.60) PTPRCMEN1KMT2AS100A4NPC1
SCHEMBL29440306 0.91 MEN1 (0.60) PTPRCMEN1KMT2AS100A4NPC1
SCHEMBL19230417 0.88 ALDH1A1 (0.52) PTPRCMEN1KMT2AS100A4NPC1
SCHEMBL10057987 0.85 MEN1 (0.50) PTPRCMEN1KMT2AS100A4NPC1
SCHEMBL236156 0.85 MEN1 (0.67) PTPRCMEN1KMT2AS100A4NPC1
SCHEMBL2516264 0.85 MEN1 (0.50) PTPRCMEN1KMT2AS100A4NPC1
SCHEMBL54876 0.85 MEN1 (0.50) PTPRCMEN1KMT2AS100A4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0940144-A1 BIOACTIVE POLYMER PRODUCT EBARA CORPORATION (JP) 1999-09-08 EP claimed
EP-3383405-B1 ANTIBIOTIC FIIRV 104/18 COMPLEX AND THE ISOLATED INDIVIDUAL FACTORS THEREOF FONDAZIONE ST INSUBRICO DI RICERCA PER LA VITA (IT) 2024-06-12 EP disclosed
US-20190002942-A1 ANTIBIOTIC FIIRV 104/18 COMPLEX AND THE ISOLATED INDIVIDUAL FACTORS THEREOF FONDAZIONE ISTITUTO INSUBRICO DI RICERCA PER LA VITA (IT) 2019-01-03 US disclosed
EP-3383405-A1 ANTIBIOTIC FIIRV 104/18 COMPLEX AND THE ISOLATED INDIVIDUAL FACTORS THEREOF Fondazione Istituto Insubrico di Ricerca per la Vita (IT) 2018-10-10 EP disclosed
WO-2017093114-A1 ANTIBIOTIC FIIRV 104/18 COMPLEX AND THE ISOLATED INDIVIDUAL FACTORS THEREOF FONDAZIONE ISTITUTO INSUBRICO DI RICERCA PER LA VITA (IT) 2017-06-08 WO disclosed
CN-101048422-B Benzonaphthaceneglycoside derivative and use thereof FUJIFILM CORP 2010-11-17 CN disclosed
EP-1810976-A4 BENZONAPHTHACENEGLYCOSIDE DERIVATIVE AND USE THEREOF FUJIFILM CORP (JP) 2007-10-17 EP disclosed
CN-101048422-A Benzonaphthaceneglycoside derivative and use thereof FUJIFILM CORP (JP) 2007-10-03 CN disclosed
WO-2006028229-A1 BENZONAPHTHACENEGLYCOSIDE DERIVATIVE AND USE THEREOF FUJIFILM CORPORATION (JP) 2006-03-16 WO disclosed
EP-0925284-B1 NEW POLYCYCLIC PHTHALAZIN DERIVATIVES AND THEIR USE GRUENENTHAL GMBH (DE) 2001-07-04 EP disclosed
US-6124290-A TREATING BACTERIAL INFECTIONS GRUENENTHAL GMBH (DE) 2000-09-26 US disclosed
JP-2000028599-A D-MANNOSE IDENTIFICATION AFFINITY CARRIER AND USING METHOD THEREFOR EBARA CORP 2000-01-28 JP disclosed
JP-2000001497-A BENZONAPHTHACENEQUINONE DERIVATIVE SEIKAGAKU KOGYO CO LTD 2000-01-07 JP disclosed
EP-0940144-A1 BIOACTIVE POLYMER PRODUCT EBARA CORPORATION (JP) 1999-09-08 EP disclosed
EP-0925284-A1 NEW POLYCYCLIC PHTHALAZIN DERIVATIVES AND THEIR USE Grünenthal GmbH (DE) 1999-06-30 EP disclosed
WO-1998007706-A1 NEW POLYCYCLIC PHTHALAZIN DERIVATIVES AND THEIR USE Grünenthal GmbH (DE) 1998-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190002942-A1 ANTIBIOTIC FIIRV 104/18 COMPLEX AND THE ISOLATED INDIVIDUAL FACTORS THEREOF MRPL38, F5, F8 PTPRC 3115/4885MEN1 2523/4885KMT2A 3617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.